Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial
从原研英夫利昔单抗转换至生物类似药英夫利昔单抗(CT-P13)后的长期疗效和安全性:NOR-SWITCH试验的开放标签扩展研究
期刊:Journal of Internal Medicine
影响因子:9.2
doi:10.1111/joim.12880
Goll, G L; Jørgensen, K K; Sexton, J; Olsen, I C; Bolstad, N; Haavardsholm, E A; Lundin, K E A; Tveit, K S; Lorentzen, M; Berset, I P; Fevang, B T S; Kalstad, S; Ryggen, K; Warren, D J; Klaasen, R A; Asak, Ø; Baigh, S; Blomgren, I M; Brenna, Ø; Bruun, T J; Dvergsnes, K; Frigstad, S O; Hansen, I M; Hatten, I S H; Huppertz-Hauss, G; Henriksen, M; Hoie, S S; Krogh, J; Midtgard, I P; Mielnik, P; Moum, B; Noraberg, G; Poyan, A; Prestegård, U; Rashid, H U; Strand, E K; Skjetne, K; Seeberg, K A; Torp, R; Ystrøm, C M; Vold, C; Zettel, C C; Waksvik, K; Gulbrandsen, B; Hagfors, J; Mørk, C; Jahnsen, J; Kvien, T K